Business
Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252
– Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors
About this update from Shattuck Labs, Inc.
[{"type":"text","content":"– Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2021 – – Reported initial safety data from SL-172154 (SIRPα-Fc-CD40L) Phase 1 trial in ovarian cancer suggesting an encouraging early safety profile and ability to dose escalate beyond prior CD40 agonist antibodies – – Announced plans to study SL-172154 in hematologic malignancies, Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS), with an IND filing anticipated in the fourth quarter of 2021 – – Reported plans to continue dose escalating in the SL-279252 (PD1-Fc-OX40L) Phase 1 trial in advanced solid tumors based on trends in immune response data – AUSTIN, TX and DURHAM, NC, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the second quarter ended June 30, 2021 and provided recent business highlights. “Over the past quarter we have begun to compare and contrast the immunological effects of CD40 and OX40 stimulation in cancer patients treated with SL-172154 and SL-279252. We believe the emerging data validate the hypothesis that the ARC platform can uniquely activate the TNF superfamily and indicate that the effects of OX40 stimulation are far more subtle than innate immune stimulation of CD40. We are excited to share this data in just a few months' time at the SITC Annual Meeting,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. “Discharging the perceived safety risks associated with dose-escalating a CD40 agonist has enabled us to broaden our clinical development strategy, including an expected IND application for expansion into both Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome in the fourth quarter of this year.” Second Quarter 2021 Recent Business Highlights and Other Recent Developments ARC Clinical-Stage Pipeline Continued Enrollment of SL-172154 Phase 1 Clinical Trial in Ovarian Cancer with Encouraging Safety Profile: The phase 1 trial is...